Use of benzodiazepine compound
By applying benzodiazepines or their pharmaceutically acceptable salts, various dosage forms can be prepared, solving the problem of low success rates of existing drugs in clinical trials and achieving effective treatment of agitation and applicability to a variety of diseases.
Patent Information
- Application Number
- PCT/CN2026/095024
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-07-25
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Existing stimulation therapy drugs have low success rates in clinical trials, especially in the field of neurological diseases. Preclinical studies cannot fully predict clinical outcomes, and there is an urgent need to develop new stimulation therapy drugs.
Benzodiazepines or their pharmaceutically acceptable salts are used to treat agitation or agitation-related symptoms by administering them to subjects via various routes of administration, including oral administration and injection, and prepared in different dosage forms such as solutions, tablets, capsules, and granules.
Effectively treats various types of agitation, including acute and non-acute agitation, significantly improving the success rate of agitation treatment. Applicable to a variety of mental and neurological disorders, offering flexibility and therapeutic efficacy through multiple administration methods.
Smart Images

Figure CN2026095024_12112026_PF_FP_ABST
Abstract
Description
Uses of benzodiazepines
[0001] This application, entitled "Benzodiazepines", was filed with the China National Intellectual Property Administration on May 8, 2025. Application number: 202510593420.3 The patent application for "uses of a class of compounds" was filed on July 25, 2025, with application number 202511037106.3 and application title "Benzodiazepines". Priority is claimed in the patent application for "uses of the compound", the entire contents of which are incorporated herein by reference. Technical Field
[0002] This invention belongs to the field of pharmaceutical technology, specifically relating to benzodiazepines. These compounds are used to treat agitation. Background Technology
[0003] Agitation refers to behavioral disturbances or disorders, including aggression, belligerence, hyperactivity, and disinhibition. Agitation is a nonspecific cluster of relatively unrelated behaviors that can be seen in several different clinical disorders, typically presenting a fluctuating course. Agitation can be caused by several different medical conditions and drug interactions, or by any situation that impairs cognitive function. Multiple underlying pathophysiological abnormalities are mediated by dysregulation of the dopaminergic, serotonergic, norepinephrine, and GABAergic systems. A key characteristic of agitation is motor impairment (akathisia). Early intervention is crucial for safety to prevent agitation from progressing to aggressive and violent behavior.
[0004] Agitation may be associated with neurodegenerative diseases. One of the key manifestations of a long-term, progressive neurodegenerative process is clinically known as dementia. Dementia includes Alzheimer's disease (AD), frontotemporal dementia (FTD), vascular dementia, Lewy body disease (LBD), and Down dementia. Adult-onset dementia gradually destroys a person's memory and ability to learn, reason, make judgments, communicate, and perform daily activities. In later stages, patients may experience personality and behavioral changes such as anxiety, suspicion, agitation, and aggression.
[0005] Agitation can also be associated with neuropsychiatric disorders (such as schizophrenia), bipolar disorders (such as bipolar disorder or mania), depression, delirium, or alcohol and drug withdrawal. Acute agitation, characterized by restlessness and accompanying mental tension, is a serious medical problem that can occur in certain mental illnesses (including schizophrenia and bipolar mania) and can rapidly escalate into aggressive behavior. Acute agitation is characterized by pacing, hand-wringing, fist-clenching, forced speech, shouting, and threatening physical signs of escalating agitation.
[0006] Currently, commonly used drugs for treating agitation in clinical practice include beta-blockers such as propranolol and indolol; anti-anxiety drugs such as buspirone; anticonvulsants such as valproate and lamotrigine; antipsychotics such as haloperidol, droperidol, and ziprasidone; as well as other highly effective dopamine blockers and atypical antipsychotics such as olanzapine, but certain limitations still exist.
[0007] Compounds undergo numerous trials from research and development to market launch, with clinical trials being a crucial hurdle far exceeding preclinical research, directly determining whether a drug can be successfully launched. Preclinical research only provides preliminary theoretical basis for drugs and cannot replicate human characteristics, while clinical trials are the ultimate test to verify the efficacy and safety of drugs in humans for the first time, serving as an essential bridge connecting basic research and clinical application. Clinical data shows that the overall success rate of drug clinical trials has been only around 8% in recent years, with over 90% of compounds failing at this stage. In the field of neurological diseases, the overall success rate of clinical trials has hit a low of 3.5%, with stringent screening at each stage, and the success rate of Phase II clinical trials being a core bottleneck (Nat Commun. 2025 Oct 29; 16(1):9537.). Preclinical research can be repeatedly optimized, while failure in clinical trials means termination of market launch. Therefore, the results of preclinical trials cannot completely predict the success or failure of clinical trials, as clinical results themselves are unpredictable.
[0008] Therefore, developing new drugs with therapeutic effects on agitation is of great significance. Summary of the Invention
[0009] This invention aims to provide a method for treating agitation or agitation-related signs, the method comprising administering benzodiazepine of Formula I to the subject. Class of compounds or their pharmaceutically acceptable salts;
[0010] This invention provides a method for treating agitation or agitation-related signs in a subject in need, the method comprising administering to the subject an effective amount of benzodiazepine (Formula I). Class of compounds or their pharmaceutically acceptable salts;
[0011] The present invention also provides a method for treating acute agitation or acute agitation-related signs in a subject in need, the method comprising administering to the subject an effective amount of benzodiazepine (Formula I). Class of compounds or their pharmaceutically acceptable salts;
[0012] The present invention also provides a method for treating agitation or agitation-related signs in a subject in need, the method comprising administering to the subject an effective amount of benzodiazepine (Formula I). Preparations of such compounds or their pharmaceutically acceptable salts;
[0013] The present invention also provides a method for treating acute agitation or acute agitation-related signs in a subject in need, the method comprising administering to the subject an effective amount of benzodiazepine (Formula I). Preparations of such compounds or their pharmaceutically acceptable salts;
[0014] The present invention also provides a method for treating agitation or agitation-related signs in a subject in need, the method comprising administering to the subject an effective amount of benzodiazepine (Formula I). A solution of a class of compounds or a pharmaceutically acceptable salt thereof; or administration to a subject of an effective amount of benzodiazepines of formula I. Tablets containing a class of compounds or their pharmaceutically acceptable salts; or administration to a subject of an effective amount of benzodiazepines as shown in Formula I. Capsules of a class of compounds or their pharmaceutically acceptable salts; or administration to a subject of an effective amount of benzodiazepines of formula I. Granules of a class of compounds or their pharmaceutically acceptable salts; or administration to a subject of an effective amount of benzodiazepines as shown in Formula I. Suspensions of such compounds or their pharmaceutically acceptable salts;
[0015] The present invention also provides a method for treating acute agitation or acute agitation-related signs in a subject in need, the method comprising administering to the subject an effective amount of benzodiazepine (Formula I). A solution of a class of compounds or a pharmaceutically acceptable salt thereof; or administration to a subject of an effective amount of benzodiazepines of formula I. Tablets containing a class of compounds or their pharmaceutically acceptable salts; or administration to a subject of an effective amount of benzodiazepines as shown in Formula I. Capsules of a class of compounds or their pharmaceutically acceptable salts; or administration to a subject of an effective amount of benzodiazepines of formula I. Granules of a class of compounds or their pharmaceutically acceptable salts; or administration to a subject of an effective amount of benzodiazepines as shown in Formula I. Suspensions of such compounds or their pharmaceutically acceptable salts;
[0016] The present invention also provides a method for treating agitation or agitation-related signs in a subject in need, the method comprising administering to the subject an effective amount of benzodiazepine (Formula I). Capsules of a class of compounds or their pharmaceutically acceptable salts;
[0017] The present invention also provides a method for treating acute agitation or acute agitation-related signs in a subject in need, the method comprising administering to the subject an effective amount of benzodiazepine (Formula I). Capsules of a class of compounds or their pharmaceutically acceptable salts;
[0018] In some embodiments, the administration of an effective amount of benzodiazepine of formula I to the subject Class of compounds or their pharmaceutically acceptable capsules;
[0019] In some embodiments, the administration of an effective amount of benzodiazepine of formula I to the subject A solution of a class of compounds or a pharmaceutically acceptable salt thereof, preferably benzodiazepines as shown in Formula I. Injection of a class of compounds or a pharmaceutically acceptable salt thereof or benzodiazepines as shown in Formula I Oral solutions of such compounds or their pharmaceutically acceptable salts, etc.;
[0020] In some embodiments, the administration of an effective amount of benzodiazepine of formula I to the subject A solution of a class of compounds or a pharmaceutically acceptable salt thereof, preferably benzodiazepines as shown in Formula I. Sodium chloride solution of a class of compounds or a pharmaceutically acceptable salt thereof, or benzodiazepines as shown in Formula I glucose solutions of such compounds or their pharmaceutically acceptable salts;
[0021] In some embodiments, the agitation or agitation-related signs of the subject in need are agitation or agitation-related signs of patients with depressive disorders (e.g., major depressive disorder), schizophrenia and other psychotic disorders (e.g., schizophrenia, schizoaffective disorder, catatonia), bipolar and related disorders (e.g., bipolar I disorder, bipolar II disorder), neurocognitive disorders (e.g., moderate to severe neurocognitive disorders, delirium), or substance / drug-induced mental disorders.
[0022] In some embodiments, the arousal is psychomotor arousal;
[0023] In some embodiments, the agitation is acute agitation;
[0024] In some embodiments, the agitation of the subject in need is agitation of a patient with a neuropsychiatric disorder (such as schizophrenia, bipolar disorder, bipolar mania, delirium, or depression).
[0025] In some embodiments, the acute agitation of the subject in need is acute agitation in patients with neuropsychiatric disorders (such as schizophrenia, bipolar disorder, bipolar mania, delirium, or depression).
[0026] In some embodiments, the agitation of the desired subject is agitation of schizophrenia;
[0027] In some embodiments, the acute agitation of the subject in need is acute agitation of schizophrenia;
[0028] In some embodiments, the agitation of the desired subject is agitation in patients with neurodegenerative diseases (such as dementia, Alzheimer's disease, frontotemporal dementia, or Parkinson's disease).
[0029] In some embodiments, the acute agitation of the subject in need is acute agitation in patients with neurodegenerative diseases (such as dementia, Alzheimer's disease, frontotemporal dementia, or Parkinson's disease).
[0030] In some embodiments, the agitation of the desired subject is agitation caused or resulting from alcohol or drug abuse;
[0031] In some embodiments, the acute agitation of the subject in need is acute agitation caused or resulting from alcohol or drug abuse;
[0032] The present invention also provides a benzodiazepine of formula I. These compounds or their pharmaceutically acceptable salts are used to treat agitation or agitation-related symptoms;
[0033] The present invention also provides a benzodiazepine of formula I. These compounds or their pharmaceutically acceptable salts are used to treat acute agitation or signs associated with acute agitation.
[0034] The present invention also provides a benzodiazepine of formula I. A solution of a compound or a pharmaceutically acceptable salt thereof is used to treat agitation or agitation-related symptoms;
[0035] The present invention also provides a benzodiazepine of formula I. This type of compound or a pharmaceutically acceptable salt solution thereof is used to treat acute agitation or signs associated with acute agitation;
[0036] The present invention also provides a benzodiazepine of formula I. These compounds or their pharmaceutically acceptable salts are used to prepare drugs for treating agitation or agitation-related symptoms;
[0037] The present invention also provides a benzodiazepine of formula I. These compounds or their pharmaceutically acceptable salts are used to prepare drugs for treating acute agitation or signs associated with acute agitation;
[0038] The present invention also provides a benzodiazepine of formula I. The compound or a pharmaceutically acceptable salt thereof is used to prepare a medicament for treating agitation or agitation-related symptoms, said medicament being a solution;
[0039] The present invention also provides a benzodiazepine of formula I. The compound or a pharmaceutically acceptable salt thereof is used to prepare a medicament for treating acute agitation or signs associated with acute agitation, said medicament being a solution;
[0040] The present invention also provides a benzodiazepine of formula I. The compound or a pharmaceutically acceptable salt thereof is used to prepare a medicament for treating agitation or agitation-related symptoms, said medicament being a capsule;
[0041] The present invention also provides a benzodiazepine of formula I. The compound or a pharmaceutically acceptable salt thereof is used to prepare a medicament for treating acute agitation or signs associated with acute agitation, said medicament being a capsule;
[0042] The present invention also provides a benzodiazepine of formula I. Use of class of compounds or pharmaceutically acceptable salts thereof in the preparation of medicaments for the treatment of agitation or agitation-related symptoms;
[0043] The present invention also provides a benzodiazepine of formula I. Use of class of compounds or pharmaceutically acceptable salts thereof in the preparation of medicaments for the treatment of acute agitation or signs associated with acute agitation;
[0044] The present invention also provides a benzodiazepine of formula I. Use of a class of compounds or pharmaceutically acceptable salts thereof in the preparation of a medicament for treating agitation or agitation-related signs, said medicament being a solution;
[0045] The present invention also provides a benzodiazepine of formula I. Use of a class of compounds or pharmaceutically acceptable salts thereof in the preparation of a medicament for treating acute agitation or signs associated with acute agitation, said medicament being a solution;
[0046] The present invention also provides a benzodiazepine of formula I. Use of a class of compounds or pharmaceutically acceptable salts thereof in the preparation of a medicament for treating agitation or agitation-related signs, said medicament being a capsule;
[0047] The present invention also provides a benzodiazepine of formula I. Use of a class of compounds or pharmaceutically acceptable salts thereof in the preparation of a medicament for treating acute agitation or signs associated with acute agitation, said medicament being a capsule;
[0048] The present invention also provides a method for treating, preventing, or alleviating agitation or agitated signs in a subject in need, wherein the agitation is agitation in a patient with schizophrenia, bipolar disorder, bipolar mania, delirium, depression, or other psychoneurotic disorders, the method comprising administering to the subject an effective amount of benzodiazepine of formula I. Class of compounds or their pharmaceutically acceptable salts;
[0049] The present invention also provides a method for treating, preventing, or alleviating acute agitation or signs of acute agitation in a subject in need, wherein the acute agitation is acute agitation in a patient with schizophrenia, bipolar disorder, bipolar mania, delirium, depression, or other psychoneurotic disorders, the method comprising administering to the subject an effective amount of benzodiazepine (Formula I). Class of compounds or their pharmaceutically acceptable salts;
[0050] The present invention also provides a method for treating, preventing, or alleviating agitation or agitated signs in a subject in need, wherein the agitation is agitation in a patient with schizophrenia, bipolar disorder, bipolar mania, delirium, depression, or other psychoneurotic disorders, the method comprising administering to the subject an effective amount of benzodiazepine of formula I. A solution of a compound of the class I; or administration to the subject an effective amount of benzodiazepines of formula I. Tablets of a class of compounds or their pharmaceutically acceptable salts; or administration to a subject an effective amount of benzodiazepines of formula I. Capsules of a class of compounds or their pharmaceutically acceptable salts; or administration to a subject an effective amount of benzodiazepines of formula I. Granules of a class of compounds or their pharmaceutically acceptable salts; or administration to a subject of an effective amount of benzodiazepines of formula I. Suspensions of such compounds or their pharmaceutically acceptable salts;
[0051] The present invention also provides a method for treating, preventing, or alleviating acute agitation or signs of acute agitation in a subject in need, wherein the acute agitation is acute agitation in a patient with schizophrenia, bipolar disorder, bipolar mania, delirium, depression, or other psychoneurotic disorders, the method comprising administering to the subject an effective amount of benzodiazepine (Formula I). A solution of a compound of the class I; or administration to the subject an effective amount of benzodiazepines of formula I. Tablets of a class of compounds or their pharmaceutically acceptable salts; or administration to a subject an effective amount of benzodiazepines of formula I. Capsules of a class of compounds or their pharmaceutically acceptable salts; or administration to a subject an effective amount of benzodiazepines of formula I. Granules of a class of compounds or their pharmaceutically acceptable salts; or administration to a subject of an effective amount of benzodiazepines of formula I. Suspensions of such compounds or their pharmaceutically acceptable salts;
[0052] The present invention also provides a method for treating, preventing, or alleviating agitation or agitated signs in a subject in need, wherein the agitation is agitation in a patient with dementia, Alzheimer's disease, frontotemporal dementia, Parkinson's disease, or other neurodegenerative diseases, the method comprising administering to the subject an effective amount of benzodiazepine of formula I. Class of compounds or their pharmaceutically acceptable salts;
[0053] The present invention also provides a method for treating, preventing, or alleviating acute agitation or signs of acute agitation in a subject in need, wherein the acute agitation is acute agitation in a patient with dementia, Alzheimer's disease, frontotemporal dementia, Parkinson's disease, or other neurodegenerative diseases, the method comprising administering to the subject an effective amount of benzodiazepine of Formula I. Class of compounds or their pharmaceutically acceptable salts;
[0054] The present invention also provides a method for treating, preventing, or alleviating agitation or agitated signs in a subject in need, wherein the agitation is agitation in a patient with dementia, Alzheimer's disease, frontotemporal dementia, Parkinson's disease, or other neurodegenerative diseases, the method comprising administering to the subject an effective amount of benzodiazepine of formula I. A solution of a benzodiazepine compound or a pharmaceutically acceptable salt thereof; or administration to a subject an effective amount of a benzodiazepine of formula I. Tablets of a class of compounds or their pharmaceutically acceptable salts; or administration to a subject an effective amount of benzodiazepines of formula I. Capsules of a class of compounds or their pharmaceutically acceptable salts; or administration to a subject an effective amount of benzodiazepines of formula I. Granules of a class of compounds or their pharmaceutically acceptable salts; or administration to a subject of an effective amount of benzodiazepines of formula I. Suspensions of such compounds or their pharmaceutically acceptable salts;
[0055] The present invention also provides a method for treating, preventing, or alleviating acute agitation or signs of acute agitation in a subject in need, wherein the acute agitation is acute agitation in a patient with dementia, Alzheimer's disease, frontotemporal dementia, Parkinson's disease, or other neurodegenerative diseases, the method comprising administering to the subject an effective amount of benzodiazepine of Formula I. A solution of a benzodiazepine compound or a pharmaceutically acceptable salt thereof; or administration to a subject an effective amount of a benzodiazepine of formula I. Tablets of a class of compounds or their pharmaceutically acceptable salts; or administration to a subject an effective amount of benzodiazepines of formula I. Capsules of a class of compounds or their pharmaceutically acceptable salts; or administration to a subject an effective amount of benzodiazepines of formula I. Granules of a class of compounds or their pharmaceutically acceptable salts; or administration to a subject of an effective amount of benzodiazepines of formula I. Suspensions of such compounds or their pharmaceutically acceptable salts;
[0056] The present invention also provides a method for treating, preventing, or alleviating agitation or agitation-related signs in a subject in need, the method comprising administering to the subject 1 to 600 mg of benzodiazepine of Formula I. This class of compounds or their pharmaceutically acceptable salts; preferably, administration of 1 to 500 mg of benzodiazepines of Formula I. Class I compounds or their pharmaceutically acceptable salts; more preferably, administration of 1–150 mg of benzodiazepines of Formula I. The compound or a pharmaceutically acceptable salt thereof; more preferably, 1 to 100 mg of benzodiazepine of formula I is administered. Class I compounds or their pharmaceutically acceptable salts; more preferably, administration of 5-50 mg of benzodiazepines of Formula I. The compound or a pharmaceutically acceptable salt thereof; more preferably, 5 to 30 mg (e.g., 5 mg, 10 mg, 20 mg, etc.) of benzodiazepine of formula I is administered. A class of compounds or their pharmaceutically acceptable salts; more preferably, administration of 2–8 mg of benzodiazepine of formula I. Class of compounds or their pharmaceutically acceptable salts;
[0057] In some embodiments, the agitation or agitation-related signs are acute agitation or acute agitation-related signs;
[0058] The present invention also provides a method for treating, preventing, or alleviating agitation or agitation-related signs in a subject in need, the method comprising administering to the subject a benzodiazepine containing formula I. Combinations of class of compounds or their pharmaceutically acceptable salts;
[0059] The present invention also provides a benzodiazepine containing the formula I. Use of a combination of a class of compounds or pharmaceutically acceptable salts thereof for the treatment, prevention or relief of agitation or agitation-related signs in a subject in need;
[0060] The present invention also provides a benzodiazepine containing the formula I. The use of a combination of such compounds or pharmaceutically acceptable salts thereof in the preparation of a medicament for the treatment, prevention or relief of agitation or agitation-related signs in a subject in need;
[0061] In some embodiments, the composition comprises 1 to 600 mg of benzodiazepine of Formula I. The composition comprises a class of compounds or a pharmaceutically acceptable salt thereof; preferably, the composition comprises 1 to 500 mg of benzodiazepine of formula I. The composition comprises a class of compounds or a pharmaceutically acceptable salt thereof; more preferably, the composition comprises 1 to 150 mg of benzodiazepine of formula I. The composition comprises a class of compounds or a pharmaceutically acceptable salt thereof; more preferably, the composition comprises 1 to 100 mg of benzodiazepine of formula I. The composition comprises a class of compounds or a pharmaceutically acceptable salt thereof; more preferably, the composition comprises 5 to 50 mg of benzodiazepine of formula I. The composition comprises a class of compounds or a pharmaceutically acceptable salt thereof; more preferably, the composition comprises 5 to 30 mg (e.g., 5 mg, 10 mg, 20 mg, etc.) of benzodiazepine of formula I. The composition comprises a class of compounds or a pharmaceutically acceptable salt thereof; more preferably, the composition comprises 2 to 8 mg of benzodiazepine of formula I. Class of compounds or their pharmaceutically acceptable salts;
[0062] In some embodiments, the agitation or agitation-related signs are acute agitation or signs associated with acute agitation.
[0063] In some embodiments, the agitation or agitation-related signs of the subject in need are agitation or agitation-related signs of patients with depressive disorders (e.g., major depressive disorder), schizophrenia and other psychotic disorders (e.g., schizophrenia, schizoaffective disorder, catatonia), bipolar and related disorders (e.g., bipolar I disorder, bipolar II disorder), neurocognitive disorders (e.g., moderate to severe neurocognitive disorders, delirium), or substance / drug-induced mental disorders.
[0064] In some embodiments, the arousal is psychomotor arousal;
[0065] In some embodiments, the composition comprises benzodiazepines of Formula I. Class of compounds or their pharmaceutically acceptable salts, and one or more pharmaceutically acceptable pharmaceutical carriers, excipients and / or diluents;
[0066] In some embodiments, the composition may be formulated into any pharmaceutically acceptable dosage form, such as an oral formulation or a dosage form other than an oral formulation;
[0067] In some embodiments, the benzodiazepine shown in Formula I A solution of a class of compounds or their pharmaceutically acceptable salts is a benzodiazepine (as shown in Formula I). It is prepared by dissolving a class of compounds or their pharmaceutically acceptable salts in water;
[0068] In some embodiments, the benzodiazepine shown in Formula I Benzadiazine of Formula I in solution of a class of compounds or their pharmaceutically acceptable salts The concentration of the compound or its pharmaceutically acceptable salt is 0.001-20 mg / ml;
[0069] In some embodiments, the benzodiazepine shown in Formula I Benzadiazine of Formula I in solution of a class of compounds or their pharmaceutically acceptable salts The concentration of the compound or its pharmaceutically acceptable salt is 0.3 mg / ml;
[0070] In some embodiments, the benzodiazepine shown in Formula I Capsules of benzodiazepines or their pharmaceutically acceptable salts are those containing the compounds shown in Formula I. The compound or its pharmaceutically acceptable salt is prepared with other excipients;
[0071] In some embodiments, the benzodiazepine shown in Formula I Benzadiazine of Formula I in capsules containing a class of compounds or their pharmaceutically acceptable salts The dosage of this type of compound or its pharmaceutically acceptable salt is 3–600 mg;
[0072] In some embodiments, the benzodiazepine shown in Formula I Benzadiazine of Formula I in capsules containing a class of compounds or their pharmaceutically acceptable salts The dosage of this type of compound or its pharmaceutically acceptable salt is 3–500 mg;
[0073] In some embodiments, the benzodiazepine shown in Formula I Benzadiazine of Formula I in capsules containing a class of compounds or their pharmaceutically acceptable salts The dosage of this type of compound or its pharmaceutically acceptable salt is 3–150 mg;
[0074] In some embodiments, the benzodiazepine shown in Formula I Benzadiazine of Formula I in capsules containing a class of compounds or their pharmaceutically acceptable salts The dosage of this type of compound or its pharmaceutically acceptable salt is 3–100 mg;
[0075] In some embodiments, the benzodiazepine shown in Formula I Benzadiazine of Formula I in capsules containing a class of compounds or their pharmaceutically acceptable salts The dosage of this type of compound or its pharmaceutically acceptable salt is 5–50 mg;
[0076] In some embodiments, the benzodiazepine shown in Formula I Benzadiazine of Formula I in capsules containing a class of compounds or their pharmaceutically acceptable salts The dosage of this type of compound or its pharmaceutically acceptable salt is 5–30 mg;
[0077] In some embodiments, the benzodiazepine shown in Formula I Benzadiazine of Formula I in capsules containing a class of compounds or their pharmaceutically acceptable salts The dosage of this type of compound or its pharmaceutically acceptable salt is 2–8 mg;
[0078] In some embodiments, the benzodiazepine shown in Formula I Benzadiazine of Formula I in capsules containing a class of compounds or their pharmaceutically acceptable salts The dosage of this type of compound or its pharmaceutically acceptable salt is 5 mg;
[0079] In some embodiments, the benzodiazepine shown in Formula I Benzadiazine of Formula I in capsules containing a class of compounds or their pharmaceutically acceptable salts The dosage of this type of compound or its pharmaceutically acceptable salt is 10 mg;
[0080] In some embodiments, the benzodiazepine shown in Formula I Benzadiazine of Formula I in capsules containing a class of compounds or their pharmaceutically acceptable salts The dosage of this type of compound or its pharmaceutically acceptable salt is 20 mg;
[0081] This invention also provides a method for treating, preventing, or alleviating agitation or agitation-related signs in a subject in need, wherein the agitation or agitation-related signs are those of patients with depressive disorders (e.g., major depressive disorder), schizophrenia and other psychotic disorders (e.g., schizophrenia, schizoaffective disorder, catatonia), bipolar and related disorders (e.g., bipolar I disorder, bipolar II disorder), neurocognitive disorders (e.g., moderate to severe neurocognitive disorders, delirium), or substance / drug-induced mental disorders. The method comprises administering to the subject an effective amount of benzodiazepine (Formula I) via a route of administration other than oral administration or via oral administration. Class of compounds or their pharmaceutically acceptable salts;
[0082] In some embodiments, the agitation or agitation-related signs are acute agitation or acute agitation-related signs;
[0083] In some embodiments, the administration of an effective amount of benzodiazepine of formula I via oral administration The dosage of the compound or its pharmaceutically acceptable salt is 1 to 600 mg; preferably 1 to 500 mg; more preferably 1 to 150 mg; further preferably 1 to 100 mg; even more preferably 5 to 50 mg; even more preferably 5 to 30 mg (e.g., 5 mg, 10 mg, 20 mg, etc.); even more preferably 2 to 8 mg;
[0084] In some embodiments, the benzodiazepine shown in Formula I The dosage of benzodiazepines of Formula I, other than oral administration (e.g., injection), is the same as the oral dosage of 1-600 mg. The compounds or their pharmaceutically acceptable salts have substantially the same or equivalent therapeutic effects; preferably, they are similar to benzodiazepines of Formula I administered at an oral dose of 1-500 mg. The compounds or their pharmaceutically acceptable salts have substantially the same or equivalent therapeutic effects; more preferably, they are similar to benzodiazepines of Formula I administered at an oral dose of 1-150 mg. The compounds or their pharmaceutically acceptable salts have substantially the same or equivalent therapeutic effects; more preferably, they are similar to benzodiazepines of Formula I administered at an oral dose of 1-100 mg. The compounds or their pharmaceutically acceptable salts have substantially the same or equivalent therapeutic effects; more preferably, they are similar to benzodiazepines of Formula I administered at an oral dose of 5-50 mg. The compounds or their pharmaceutically acceptable salts have substantially the same or equivalent therapeutic effects; more preferably, they are similar to benzodiazepines of Formula I administered at an oral dose of 5-30 mg (e.g., 5 mg, 10 mg, 20 mg, etc.). The compounds or their pharmaceutically acceptable salts have substantially the same or equivalent therapeutic effects; more preferably, they are similar to benzodiazepines of Formula I administered at an oral dose of 2-8 mg. These compounds or their pharmaceutically acceptable salts have essentially the same or equivalent therapeutic effects;
[0085] In some embodiments, the other routes of administration besides oral administration are selected from injection administration, inhalation administration, topical administration, rectal administration, vaginal administration, sublingual administration, nasal administration, ocular administration, etc.
[0086] In some embodiments, the injection administration is selected from intravenous injection, intramuscular injection, subcutaneous injection, intradermal injection, intrathecal injection, intra-articular injection, etc.
[0087] This invention also provides a method for treating, preventing, or alleviating agitation or agitation-related signs in a subject in need, wherein the agitation or agitation-related signs are those of patients with depressive disorders (e.g., major depressive disorder), schizophrenia and other psychotic disorders (e.g., schizophrenia, schizoaffective disorder, catatonia), bipolar and related disorders (e.g., bipolar I disorder, bipolar II disorder), neurocognitive disorders (e.g., moderate to severe neurocognitive disorders, delirium), or substance / drug-induced mental disorders. The method comprises administering to the subject an effective amount of benzodiazepine (Formula I). Dosage forms and oral formulations other than oral formulations of the same compound or its pharmaceutically acceptable salts;
[0088] In some embodiments, the agitation or agitation-related signs are acute agitation or acute agitation-related signs;
[0089] In some embodiments, the benzodiazepine shown in Formula I Benzodiazepines of Formula I are oral formulations of compounds or their pharmaceutically acceptable salts. The dosage of the compound or its pharmaceutically acceptable salt is 1–600 mg; preferably 1–500 mg; more preferably 1–150 mg; further preferably 1–100 mg; even more preferably 5–50 mg; even more preferably 5–30 mg; even more preferably 2–8 mg;
[0090] In some embodiments, the benzodiazepine shown in Formula I Dosage of benzodiazepines of Formula I other than oral formulations (such as injections) of the same compound or its pharmaceutically acceptable salts, with a dosage of 1-600 mg. Oral formulations (e.g., capsules) of the same class of compounds or their pharmaceutically acceptable salts have substantially the same or equivalent therapeutic effects; preferably, they are similar to benzodiazepines of Formula I at doses of 1–500 mg. Oral formulations (e.g., capsules) of the same class of compounds or their pharmaceutically acceptable salts have substantially the same or equivalent therapeutic effects; more preferably, they have the same therapeutic effects as benzodiazepines of Formula I at doses of 1–150 mg. Oral formulations (e.g., capsules) of the same class of compounds or their pharmaceutically acceptable salts have substantially the same or equivalent therapeutic effects; more preferably, they are similar to benzodiazepines of Formula I at doses of 1–100 mg. Oral formulations (e.g., capsules) of the same class of compounds or their pharmaceutically acceptable salts have substantially the same or equivalent therapeutic effects; more preferably, they are similar to benzodiazepines of Formula I at doses of 5–50 mg. Oral formulations (e.g., capsules) of the same class of compounds or their pharmaceutically acceptable salts have substantially the same or equivalent therapeutic effects; more preferably, they are similar to benzodiazepines of Formula I at doses of 5–30 mg. Oral formulations (e.g., capsules) of the same class of compounds or their pharmaceutically acceptable salts have substantially the same or equivalent therapeutic effects; more preferably, they are similar to benzodiazepines of Formula I at a dose of 2–8 mg. Oral formulations (e.g., capsules) of the same class of compounds or their pharmaceutically acceptable salts have substantially the same or equivalent therapeutic effects;
[0091] In some embodiments, the dosage form other than oral preparations is selected from injections, inhalations, topical preparations, mucosal preparations, cavity preparations, etc.
[0092] In some embodiments, the injection is a dosage form that is administered by injection, such as an injection solution (water injection), an injection emulsion, an injection suspension, a sterile powder for injection (powder injection), etc.
[0093] In some embodiments, the inhalation formulation may be selected from aerosols, inhaled powders, nebulizers, etc.
[0094] In some embodiments, the mucosal preparation may be selected from eye drops, eye ointments, nasal drops, nasal sprays, sublingual tablets, oral patches, suppositories, lotions, etc.
[0095] In some embodiments, the cavity preparation may be selected from rectal suppositories, enemas, etc.
[0096] In some embodiments, the oral preparation is a dosage form that is administered orally, such as tablets, capsules, pellets, granules, oral solutions, suspensions, etc.
[0097] The benzodiazepines represented by Formula I in this invention The compound or its pharmaceutically acceptable salt can restore subjects with agitation or agitation-related signs to a level of essentially normal behavior;
[0098] The benzodiazepines represented by Formula I in this invention These compounds or their pharmaceutically acceptable salts were able to restore subjects (e.g., mice) with positive symptoms of schizophrenia (hyperactivity) to a level of essentially normal behavior.
[0099] The benzodiazepines represented by Formula I in this invention These compounds or their pharmaceutically acceptable salts were able to restore the range of motion in subjects (e.g., mice) with positive symptoms of schizophrenia (hyperactivity) to near-normal behavioral levels.
[0100] The benzodiazepines represented by Formula I in this invention The compounds or their pharmaceutically acceptable salts have virtually no effect on the normal behavior of normal subjects (e.g., mice);
[0101] In some embodiments, the subjects exhibiting positive symptoms of schizophrenia (hyperactivity) are mice, which are induced to develop these symptoms by intraperitoneal injection of 0.3 mg / kg Dizocilpine.
[0102] In some embodiments, the benzodiazepine shown in Formula I The compound or a pharmaceutically acceptable salt thereof is administered in solution form; preferably, the solution is a physiological saline solution of compound I; more preferably, the concentration of the physiological saline solution of compound I is 0.3 mg / mL;
[0103] In some embodiments, the benzodiazepine shown in Formula I The dosage of this type of compound or its pharmaceutically acceptable salt is 3 mg / kg;
[0104] In some embodiments, the benzodiazepine shown in Formula I The compound or a pharmaceutically acceptable salt thereof is administered by injection; preferably, by intraperitoneal injection.
[0105] In this invention, the subject is benzodiazepine (BCP) as shown in Formula I. The response rate of the compound or its pharmaceutically acceptable salt is ≥50%; preferably, the response rate is ≥70%; more preferably, the response rate is ≥80%; further preferably, the response rate is ≥90%; and even more preferably, the response rate is 100%.
[0106] The benzodiazepines represented by Formula I in this invention The compound or its pharmaceutically acceptable salt can reduce agitation or agitation-related signs in subjects from moderate to severe levels to below mild levels; preferably, from moderate to severe levels to essentially normal behavioral levels;
[0107] In some embodiments, the subject is a human (preferably an adult); more preferably, the subject is a patient with schizophrenia (preferably an adult patient with schizophrenia); even more preferably, the subject is a subject diagnosed with schizophrenia agitation by ICD-10 and whose baseline positive and negative symptom scale-excitement factor subscale (PANSS-EC) score is ≥14;
[0108] This invention provides a method for reducing a subject's PANSS-EC score, wherein the method involves administering an effective amount of benzodiazepine (Formula I) to the subject. Class of compounds or their pharmaceutically acceptable salts;
[0109] In some embodiments, the reduction of the subject's PANSS-EC score is from a PANSS-EC score ≥14 to a PANSS-EC score ≤10; preferably, it is reduced to a PANSS-EC score ≤7; more preferably, it is reduced to a PANSS-EC score of 5.
[0110] In some embodiments, the reduction of the subject's PANSS-EC score means that the PANSS-EC score is reduced to ≤10 points 2 hours after administration; preferably, it is reduced to ≤7 points; more preferably, it is reduced to 5 points.
[0111] In some embodiments, the benzodiazepine shown in Formula I The effective amount of the compound or its pharmaceutically acceptable salt is 1-600 mg; preferably 1-500 mg; more preferably 1-300 mg; further preferably 1-150 mg; even more preferably 1-100 mg; even more preferably 1-50 mg; even more preferably 1-30 mg; even more preferably 1-20 mg; even more preferably 1-10 mg;
[0112] In some embodiments, the benzodiazepine shown in Formula I The compound or its pharmaceutically acceptable salt is administered orally; preferably, the oral administration is once daily, 1-600 mg each time; more preferably, once daily, 1-500 mg; more preferably, once daily, 1-300 mg; further preferably, once daily, 1-150 mg; even more preferably, once daily, 1-100 mg; even more preferably, once daily, 1-50 mg; even more preferably, once daily, 1-30 mg; even more preferably, once daily, 1-20 mg; even more preferably, once daily, 1-10 mg.
[0113] The benzodiazepines represented by Formula I in this invention When a class of compounds or their pharmaceutically acceptable salts are used to treat agitation or agitation-related signs (preferably acute agitation or acute agitation-related signs), the subjects experience a low incidence or severity of specific adverse reactions (such as somnolence, respiratory depression, etc.), and the safety and / or tolerability are acceptable.
[0114] The signs of agitation or agitation-related symptoms, or acute agitation or acute agitation-related symptoms, described in this invention are restlessness and excitement.
[0115] The agitation or agitation-related signs, or acute agitation or acute agitation-related signs, described in this invention are symptoms and signs that affect the emotional state.
[0116] The benzodiazepines represented by Formula I in this invention Solutions of such compounds or their pharmaceutically acceptable salts may be administered by injection or orally, with no specific restrictions on the route of administration;
[0117] The benzodiazepines represented by Formula I in this invention The compound or a pharmaceutically acceptable salt solution thereof is administered by injection, wherein the injection administration can be one or more of the following methods: intramuscular injection, intravenous injection, subcutaneous injection, intraperitoneal injection, etc.
[0118] The present invention does not limit the dosage form of the drug, which can be any medically recognized dosage form, such as common oral preparations, injections, or inhaled preparations. The oral preparations are selected, for example, from tablets, capsules, pellets, granules, oral solutions, or suspensions.
[0119] The effective amount of benzodiazepine of formula I described in this invention The amount of the compound or its pharmaceutically acceptable salt may vary depending on the severity of the symptoms to be relieved and on factors such as the subject’s disease state, age, sex and weight.
[0120] The effective amount of benzodiazepine of formula I described in this invention Benzadiazine of Formula I in preparations of compounds or their pharmaceutically acceptable salts The amount of the compound or its pharmaceutically acceptable salt may vary depending on the severity of the symptoms to be relieved and on factors such as the subject’s disease state, age, sex and weight.
[0121] The effective amount of benzodiazepine of formula I described in this invention Benzadiazine of Formula I in solution of a class of compounds or their pharmaceutically acceptable salts The amount of the compound or its pharmaceutically acceptable salt may vary depending on the severity of the symptoms to be relieved and on factors such as the subject’s disease state, age, sex and weight.
[0122] The effective amount of benzodiazepine of formula I described in this invention Benzadiazine of Formula I in tablets containing a class of compounds or their pharmaceutically acceptable salts The amount of the compound or its pharmaceutically acceptable salt may vary depending on the severity of the symptoms to be relieved and on factors such as the subject’s disease state, age, sex and weight.
[0123] The effective amount of benzodiazepine of formula I described in this invention Benzadiazine of Formula I in capsules containing a class of compounds or their pharmaceutically acceptable salts The amount of the compound or its pharmaceutically acceptable salt may vary depending on the severity of the symptoms to be relieved and on factors such as the subject’s disease state, age, sex and weight.
[0124] The effective amount of benzodiazepine of formula I described in this invention granules of benzodiazepines of formula I, or pharmaceutically acceptable salts thereof. The amount of the compound or its pharmaceutically acceptable salt may vary depending on the severity of the symptoms to be relieved and on factors such as the subject’s disease state, age, sex and weight.
[0125] The effective amount of benzodiazepine of formula I described in this invention Suspensions of benzodiazepines of formula I, or pharmaceutically acceptable salts thereof. The amount of the compound or its pharmaceutically acceptable salt may vary depending on the severity of the symptoms to be relieved and on factors such as the subject’s disease state, age, sex and weight.
[0126] In this invention, "dosage" or "administration dosage" can also be replaced with "content";
[0127] In this invention, "dosage", "administered dosage" or "content" refers to the amount of free base of the compound of formula I. That is, when a pharmaceutically acceptable salt of the compound of formula I is used as the active ingredient, the "dosage", "administered dosage" or "content" is the amount after conversion to free base.
[0128] In this invention, "response" refers to a PANSS-EC score that decreases by ≥40% from baseline 2 hours after the first administration;
[0129] In this invention, "response rate" refers to the proportion of subjects whose PANSS-EC score decreased by ≥40% 2 hours after the first administration;
[0130] In this invention, the term "subject" is intended to include any animal. In some embodiments, the subject is a human or non-human mammal, such as a mouse, rat, other rodent, rabbit, dog, cat, pig, cow, sheep, horse, or primate; in some embodiments, the subject is a human; and in some embodiments, the subject is an adult.
[0131] In this invention, the term "excitement" refers to irritability, emotional outbursts, impaired thinking, or excessive motor and verbal activity that may occur due to dysfunction of a specific brain region (such as the frontal lobe) or due to dysfunction of a neurotransmitter system (such as dopamine and norepinephrine); in this invention, agitation also includes aggression and hyperarousal in post-traumatic stress disorder; agitation can be acute or chronic.
[0132] In this invention, agitation can also be psychomotor agitation, which refers to excessive motor activity associated with feelings of inner tension. Such activity is usually aimless and repetitive, such as pacing, fidgeting, hand-wringing, pulling at clothes or skin, etc.; or agitation refers to the inability to sit still, pacing and / or hand-wringing; or pulling / rubbing at skin, clothing or other objects, as well as disruptive motor or verbal activity; or agitation is marked fidgeting and / or excessive physical activity, accompanied by anxiety; or as described in the Diagnostic and Statistical Manual of Mental Disorders or its revisions.
[0133] In this invention, agitation can be a symptom or behavioral feature of various diseases, such as (1) in depressive disorders (e.g., major depressive disorder) manifesting as almost daily psychomotor agitation (observed by others, not just subjectively experienced restlessness or lethargy); (2) in schizophrenia and other psychotic disorders: such as in schizophrenia or schizoaffective disorder manifesting as markedly disordered or catatonic behavior, where disordered behavior manifests as severely disordered goal-oriented behavior, unpredictable agitation, and aimless hyperactivity; or markedly disordered or abnormal motor behavior can manifest in various forms, from childish and foolish “silly” behavior to unpredictable agitation, any form of goal-oriented behavior may be problematic, leading to difficulties in performing daily activities; catatonic disorder (e.g., catatonic disorder related to other mental disorders, catatonic disorder due to other physical illnesses, unspecified catatonic disorder, etc.) manifesting as agitation unaffected by external stimuli; (3) in bipolar and related disorders, in bipolar I disorder or bipolar II disorder In manic episodes, psychomotor agitation (i.e., aimless, purposeless activity) is manifested. In manic or hypomanic episodes of bipolar I or bipolar II disorder, with mixed features, psychomotor agitation is manifested almost daily (observed by others, not just subjectively experienced restlessness or lethargy); (4) In neurocognitive disorders: delirium (such as hyperactive delirium) is characterized by excessive mental activity accompanied by irritability and nocturnal agitation; agitation is common in a variety of neurocognitive disorders, especially in moderate cases. In patients with severe to moderate neurocognitive impairment, agitation often occurs against a background of confusion or frustration. It can manifest as confrontational behavior, especially when resisting care procedures such as bathing or dressing. Agitation is characterized by disruptive motor or verbal activity and is likely to occur in the late stages of cognitive impairment in various neurocognitive disorders. In severe and mild neurocognitive impairment with behavioral abnormalities, it manifests as clinically significant abnormal behaviors accompanied by irritability, such as restlessness, pacing, verbal / physical aggression, etc.(5) In various substance / drug disorders or withdrawals of substance / drug-induced mental disorders, psychomotor agitation occurs during or after the use of a substance / drug / non-substance for a period of time after its use or cessation (or reduction), such as ① psychomotor agitation after alcohol withdrawal, ② restlessness or irritability after caffeine withdrawal, ③ irritability, anger or aggression after marijuana withdrawal, ④ clinically significant behavioral changes such as psychomotor agitation in phencyclidine poisoning, ⑤ psychomotor agitation after withdrawal from sedatives, hypnotics or anxiolytics, ⑥ psychomotor agitation after stimulant poisoning or withdrawal, ⑦ irritability and anger in tobacco withdrawal, ⑧ restlessness or irritability in gambling disorder, ⑨ clinically significant problem behaviors such as psychomotor agitation in moderate opioid poisoning, and ⑩ clinically significant problem behaviors such as psychomotor agitation in other (unknown) substance poisoning. Other (or unknown) functional consequences of substance withdrawal, including physical symptoms and signs, agitation, etc.; (6) almost daily psychomotor agitation (observed by others, not just subjectively experienced) during a depressive episode with transient hypomania; (7) acute agitation as seen in suicidal behavior disorder.
[0134] In this invention, "poisoning" generally refers to clinically significant symptoms that appear during or shortly after the use of a substance / drug; "withdrawal" generally refers to stopping (or reducing) the use of a substance after long-term (large) use.
[0135] In this invention, the term "excited physical signs" includes excessive physical activity (examples include: pacing, swaying, gesturing, pointing, agitation, engaging in repetitive verbal or physical behaviors), verbal aggression (e.g., shouting, speaking at an excessively loud volume, using foul language, screaming, yelling, threatening others), and physical aggression (e.g., grabbing others, pushing others, pulling others, clenching fists, resisting others, hitting others, kicking objects or people, tearing at others, biting others, throwing objects, hitting oneself, slamming doors, tearing things, and damaging property).
[0136] The positive and progressive effects of this invention: This invention provides a method for treating agitation or agitation-related signs in a subject in need, the method comprising administering to the subject an effective amount of benzodiazepine (Formula I). benzodiazepines or their pharmaceutically acceptable salts, wherein the benzodiazepines These compounds, or their pharmaceutically acceptable salts, have therapeutic effects on agitation, significantly reducing or restoring agitated behavior in subjects to normal levels.
[0137] The benzodiazepine of Formula I of the present invention These compounds, or their pharmaceutically acceptable salts, have therapeutic effects on acute agitation, significantly reducing or restoring acute agitated behavior (including acute agitation in patients with schizophrenia) to normal behavioral levels in subjects.
[0138] Instruction manual illustrations:
[0139] Figure 1: Statistical chart of mouse movement, where the vertical axis represents the total movement distance, the horizontal axis represents time, vehicle represents the normal control group, compound I represents the normal control drug group, model represents the model group, and model + compound I represents the model drug group. Specific Implementation
[0140] The present invention is further illustrated below by way of examples, but these examples do not limit the invention to the scope of the embodiments described. Experimental methods in the following examples, unless otherwise specified, were performed according to conventional methods and conditions, or as selected in the product instructions. All reagents and materials used in this invention are commercially available.
[0141] Example 1
[0142] 1.1 Experimental Drugs
[0143] Dizocilpine (MK801), MCE, production batch number HY-15084, CAS number 77086-22-7;
[0144] Preparation of Compound I solution: Weigh 2.17 mg of Compound I, add 7.233 ml of physiological saline, vortex, sonicate, and dissolve to obtain a homogeneous, clear, and transparent solution with a concentration of 0.3 mg / ml;
[0145] Preparation of MK-801: Weigh 1.7 mg of MK-801, add 56.667 ml of physiological saline, vortex, sonicate, and dissolve to obtain a homogeneous, clear, and transparent solution with a concentration of 0.03 mg / ml;
[0146] 1.2 Laboratory Animals
[0147] C57 / 6J mice (male, 6-8 weeks old) were acclimatized for 7 days in an animal facility by Spifort (Beijing) Biotechnology Co., Ltd. Four mice were housed per cage during the acclimatization period. The environment was room temperature of 23-26℃ with a 12 / 12h day / night light-dark cycle. The lights were on from 7:00 to 19:00 and off from 19:00 to 7:00 the next day.
[0148] 1.3 Experimental Design
[0149] 1.3.1 Experimental Grouping
[0150] Forty normal mice were weighed and randomly grouped and numbered according to experimental requirements. They were divided into four groups: normal control group (vehicle), normal control drug group (compound I), model group (model), and model drug group (model + compound I), with 10 mice in each group.
[0151] 1.3.2 Modeling process
[0152] Intraperitoneal injection of MK-801 (0.3 mg / kg) induced positive symptoms of schizophrenia (hyperactivity) in mice.
[0153] 1.3.3 Experimental Grouping
[0154] Gently remove the mice from their cages and soothe them for 3-5 minutes to allow them to become familiar with the scent and temperature of the experimenters. Return the mice to their cages. Repeat this process for 3 consecutive days. Two hours prior to the experiment, move the mice to the behavioral testing room for acclimatization. Before each experiment, ensure the spontaneous activity testing box is clean and odor-free. Before the experiment, place the mice in the testing box for 5 minutes to acclimatize. After acclimatization, remove the mice from the testing box. The drug administration volume is 10 mL / kg. The normal control group receives an intraperitoneal injection of physiological saline; the normal control drug group receives an intraperitoneal injection of 3 mg / kg of compound I solution; the model group receives an intraperitoneal injection of 0.3 mg / kg of MK-801 and 10 mL / kg of physiological saline; the model drug group receives an intraperitoneal injection of 0.3 mg / kg of MK-801 and 3 mg / kg of compound I solution. After administration, quickly return the mice to the spontaneous activity testing box and immediately close the shielded box door. Record the mice's activity trajectory within 30 minutes after drug administration. After the test, remove the mice from the testing box and return them to their cages. After each mouse is tested, remove the excrement left in the open space box by each mouse (spray 75% ethanol on paper towels to clean the open space box, and wipe it again with clean paper); repeat the above process until all mice have been tested.
[0155] 1.4 Observation Indicators
[0156] Mice movement was recorded over 30 minutes to collect behavioral data. Statistical differences between experimental groups were calculated using Grraphpad Prism 8.0 software. One-way ANOVA and Dunnett's multiple comparisons test were used to compare differences between groups; p < 0.05 was considered statistically significant. * p < 0.05 ** p < 0.01, *** p < 0.001; # p < 0.05 ## p < 0.01, ###p < 0.001).
[0157] The parameters of the mouse behavioral observation system are shown in Table 1, the movement distance of mice in each experimental group is shown in Table 2, and the line graph is shown in Figure 1.
[0158] Table 1 Parameters of the Mouse Behavioral Observation System
[0159] Table 2. Movement distance of mice in each experimental group
[0160] Remark:
[0161] 1) Data representation is
[0162] 2) *** Compared with the normal control group, the difference in means was statistically significant (P < 0.001);
[0163] 3) ### The difference in means compared with the model group was statistically significant (P < 0.001);
[0164] 1.5 Experimental Results
[0165] Compared with the normal control group, the model group mice showed a significant increase in movement distance, indicating that the MK801-induced mouse schizophrenia positive model was successfully established; and intraperitoneal injection of compound I solution did not affect the basic activity of the mice.
[0166] Compared with the model group, intraperitoneal injection of compound I solution significantly reduced the movement distance of MK801-induced schizophrenic mice, indicating that compound I can effectively reduce schizophrenic agitation symptoms.
[0167] Example 2
[0168] 2.1 Overall Research Design
[0169] Research ID: DDXN-202506
[0170] This is a single-center, open-label, single-arm study designed to evaluate the efficacy, safety, and tolerability of didacini capsules in adult patients (18-65 years old) with acute agitation of schizophrenia. The study was divided into three parts: Part A, Part B, and Part C.
[0171] Part A: Twelve subjects received a single oral dose of didacinib capsules (10 mg). After completing 24-hour efficacy and 48-hour safety assessments in 6 subjects, if preliminary results indicate the need to further explore the efficacy and safety of higher doses, Part B can be considered concurrently or separately.
[0172] Part B: Twelve subjects will receive a single oral dose of 20 mg dacinib capsules (tentative). The study dose for Part B will be determined based on efficacy, safety, and tolerability data obtained from previous studies.
[0173] Part C: This part includes 16 subjects. Eight subjects received a single oral dose of 5 mg dacinib capsules. After completing the 24-hour efficacy and 48-hour safety assessments for these eight subjects, the researchers and the sponsor jointly determined the study dose for the remaining eight subjects based on the assessment results.
[0174] Eligible participants (those diagnosed with schizophrenia-induced agitation by ICD-10 and with a baseline Positive and Negative Syndrome Scale-Excitement Factor Subscale (PANSS-EC) score ≥14) may be identified from outpatient, emergency room, or newly admitted patients with acute agitation or those already hospitalized for chronic underlying conditions. Participants will be placed in a research center or hospitalized for screening to determine eligibility.
[0175] After eligibility is confirmed, subjects will receive didacinib capsules at doses of 5 mg, 10 mg, or 20 mg (tentative), with only one dose administered throughout the study. During administration, subjects will take the capsules with an appropriate amount of warm water under the supervision of a healthcare professional.
[0176] Efficacy and safety will be assessed periodically after administration. If the patient's condition requires it, the investigator may, at their discretion, administer haloperidol 5-10 mg / IM to initiate standard treatment for arousal (the recommended initial dose is 5 mg / dose, repeatable hourly, with a daily dose not exceeding 20 mg / day, or the appropriate dose may be selected by the investigator based on clinical circumstances). Rescue therapy is best administered after the 24-hour assessment. Throughout the treatment period, efficacy, safety, and tolerability will be assessed at different time points; detailed information can be found in the clinical trial schedule.
[0177] Any clinically significant abnormal vital sign measurements, clinical laboratory test results, physical examinations, or electrocardiogram parameters will be repeated, including results obtained on the last study day or at early termination. Any abnormal test result deemed clinically significant will be repeated during the follow-up period until the value returns to baseline (or within the normal range), or the investigator deems the abnormality stable and no longer requires monitoring.
[0178] 2.2 Research Period
[0179] The longest period from screening to the end of the trial follow-up is 10 days.
[0180] Screening period: D-2 to D-1;
[0181] Research period: D1~D3
[0182] Safety follow-up period: D7+1.
[0183] 2.3 Evaluation Indicators
[0184] 2.3.1 Effectiveness Indicators
[0185] A preliminary evaluation of the efficacy of didacini capsules in the acute control of agitation in schizophrenia.
[0186] Key therapeutic indicators:
[0187] Two hours after administration, the PANSS-EC score changed from baseline;
[0188] Secondary efficacy endpoints:
[0189] The proportion of subjects whose PANSS-EC score decreased by ≥40% 2 hours after the first dose;
[0190] The changes in PANSS-EC scores from baseline were observed at 15, 30, 45, 60, 90 min and 4, 6, 8, 24 h after drug administration.
[0191] 2.3.2 Safety Indicators
[0192] To evaluate the tolerability and safety of didacinib capsules in subjects. To observe adverse events occurring in subjects during the clinical trial, record their clinical characteristics, severity, time of occurrence, time of termination, treatment measures, and outcomes, and determine their correlation with the investigational drug.
[0193] 2.3.3 PK Indicator
[0194] Blood samples were collected from subjects at the following time points, with approximately 4 mL of blood collected each time. The concentration of didacinib in human plasma was detected using LC-MS / MS.
[0195] Blood samples will be collected from each subject at 0.5h, 1h, 2h, and 4h after drug administration, and the blood collection time (accurate to the minute) and drug administration time will be accurately recorded. Blood samples may not be collected if the subject is uncooperative.
[0196] 2.4 Research Results
[0197] Based on 7 subjects enrolled in Part A and 3 subjects enrolled in Part C, the results showed that PANSS-EC scores decreased by more than 40% 2 hours after oral administration of 5 mg and 10 mg didacini capsules. In some patients, PANSS-EC scores decreased by more than 70%, or even returned to normal levels, indicating that didacini can effectively control acute agitation in schizophrenia. The sleep onset rate was significantly higher in subjects taking 10 mg didacini capsules than in those taking 5 mg didacini capsules.
[0198] The embodiments of the present invention have been described above. However, the present invention is not limited to the above embodiments. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the protection scope of the present invention.
Claims
1. A method of treating agitation or signs associated with agitation in a subject in need thereof, the method comprising administering to the subject an effective amount of a benzodiazepine compound represented by Formula I or a pharmaceutically acceptable salt thereof; .
2. The method of claim 1, wherein the benzodiazepine compound is represented by Formula II:
2. A method of treating agitation or signs associated with agitation in a subject in need thereof, the method comprising administering to the subject a formulation comprising an effective amount of a benzodiazepine or a pharmaceutically acceptable salt thereof represented by Formula I.
3. A method of treating agitation or signs associated with agitation in a subject in need thereof, the method comprising administering to the subject a solution comprising an effective amount of a benzodiazepine compound represented by Formula I or a pharmaceutically acceptable salt thereof; or administering to the subject a tablet comprising an effective amount of a benzodiazepine compound represented by Formula I or a pharmaceutically acceptable salt thereof; or administering to the subject a capsule comprising an effective amount of a benzodiazepine compound represented by Formula I or a pharmaceutically acceptable salt thereof; or administering to the subject a granule comprising an effective amount of a benzodiazepine compound represented by Formula I or a pharmaceutically acceptable salt thereof; or administering to the subject a suspension comprising an effective amount of a benzodiazepine compound represented by Formula I or a pharmaceutically acceptable salt thereof. 4. The method according to any one of claims 1-3, wherein the agitation of the subject in need thereof is agitation of a patient with a neuropsychiatric disease; preferably, the agitation of the subject in need thereof is agitation of a patient with schizophrenia, bipolar disorder, bipolar mania, delirium, or depression.
5. The method according to any one of claims 1-3, wherein the agitation of the subject in need thereof is agitation of a patient with a neurodegenerative disease; preferably, the agitation of the subject in need thereof is agitation of a patient with dementia, Alzheimer’s disease, frontotemporal dementia, or Parkinson’s disease.
6. The method according to any one of claims 1-3, wherein the agitation of the subject in need thereof is agitation caused or contributed by alcohol use or drug abuse.
7. A benzodiazepine compound of formula I ###0002### or a pharmaceutically acceptable salt thereof for use in the treatment of agitation or agitation-related signs.
7. A benzodiazepine compound of formula I ###0002### or a pharmaceutically acceptable salt thereof for use in the treatment of agitation or agitation-related signs.
8. A benzodiazepine compound of formula I ###0002### or a pharmaceutically acceptable salt thereof for use in therapy. for use in the treatment of agitation or agitation-related signs.
9. A benzodiazepine compound of formula I ###0002### or a pharmaceutically acceptable salt thereof for use in therapy. the use of a benzodiazepine compound of formula I ###0002### or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of agitation or agitation-related signs.
